COSCIENS Biopharma (NASDAQ:CSCI) Releases Earnings Results

COSCIENS Biopharma (NASDAQ:CSCI) posted its earnings results on Wednesday. The company reported ($2.15) earnings per share for the quarter, Zacks reports. COSCIENS Biopharma had a negative net margin of 428.43% and a negative return on equity of 95.93%.

COSCIENS Biopharma Stock Up 15.9 %

Shares of CSCI opened at $2.84 on Thursday. The company has a market cap of $10.72 million, a PE ratio of -0.24 and a beta of 1.27. The business has a fifty day moving average of $2.87 and a 200 day moving average of $3.10. COSCIENS Biopharma has a 52-week low of $1.96 and a 52-week high of $6.77.

About COSCIENS Biopharma

COSCIENS Biopharma Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.